Stemedica Cell Technologies: STEM105-M-AD / Alzheimer’s Disease

A phase 2A, multi-center, randomized, single-blind, placebo-controlled, crossover study to assess the safety, tolerability, and preliminary efficacy of a single intravenous dose of allogeneic human mesenchymal stem cells to subjects with mild to moderate dementia due to Alzheimer’s disease.